期刊
PARASITE IMMUNOLOGY
卷 42, 期 10, 页码 -出版社
WILEY
DOI: 10.1111/pim.12769
关键词
adjuvant; Chagas disease; E6020-SE; immunotherapy; TLR4 agonist; Trypanosoma cruzi; vaccine
资金
- NCRR NIH HHS [NCRR S10RR024574] Funding Source: Medline
- NIAID NIH HHS [NIAID P30AI036211] Funding Source: Medline
- NIH HHS [P30 CA125123] Funding Source: Medline
E6020 is a synthetic agonist of Toll-like receptor-4 (TLR4). The purpose of this study was to evaluate the effect of different doses of E6020-SE onTrypanosoma cruzi-specific immune responses and its ability to confer protection against acute lethal infection in mice. Forty female BALB/c were infected with 500 trypomastigotes ofT cruziH1 strain, divided into four groups (n = 10) and treated at 7- and 14-day post-infection (dpi) with different doses of E6020-SE or PBS (control). Survival was followed for 51 days, mice were euthanized and hearts were collected to evaluate parasite burden, inflammation and fibrosis. We found significantly higher survival and lower parasite burdens in mice injected with E6020-SE at all doses compared to the control group. However, E6020-SE treatment did not significantly reduce cardiac inflammation or fibrosis. On the other hand, E6020-SE modulated Th1 and Th2 cytokines, decreasing IFN-gamma and IL-4 in a dose-dependent manner after stimulation with parasite antigens. We conclude that E6020-SE alone increased survival by decreasing cardiac parasite burdens in BALB/c mice acutely infected withT cruzibut failed to prevent cardiac damage. Our results suggest that for optimal protection, a vaccine antigen is necessary to balance and orient a protective immune response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据